Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 2:53 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 13,396 matching trials from the live ClinicalTrials.gov search.
Conditions
Cervical Intraepithelial Neoplasia, Uterine Neoplasms, Genital Neoplasms, Female
Interventions
Pemetrexed
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Diabetes Mellitus, Type 2, Albuminuria
Interventions
Placebo, Canagliflozin, 100 mg, Canagliflozin, 300 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
30 Years and older
Enrollment
5,813 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
57
States / cities
Little Rock, Arkansas • Carmichael, California • Concord, California + 54 more
Conditions
Prematurity
Interventions
Human milk
Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
6 Hours to 4 Days
Enrollment
486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
4
States / cities
Birmingham, Alabama • Jackson, Mississippi • Dallas, Texas + 1 more
Conditions
Endometrial Adenocarcinoma, Metastatic Endometrial Cancer, Endometrial Cancer, Recurrent Endometrial Cancer
Interventions
anti-PD1 agent therapy - 1 year, anti-PD1 agent therapy - 2 years
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
6
States / cities
Cary, North Carolina • Chapel Hill, North Carolina • Garner, North Carolina + 2 more
Conditions
Advanced Renal Cell Carcinoma (aRCC), Metastatic Renal Cell Carcinoma ( mRCC), Clear Cell Renal Cell Carcinoma (ccRCC)
Interventions
Fianlimab, Ipilimumab, Nivolumab, Cemiplimab
Drug
Lead sponsor
Brian Rini
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Chapel Hill, North Carolina • Cleveland, Ohio + 3 more
Conditions
Recurrent Urinary Tract Infection, Postmenopause, Postmenopausal Syndrome, Postmenopausal Symptoms, Menopause
Interventions
Prasterone, Placebo
Drug
Lead sponsor
Olivia Cardenas-Trowers, M.D.
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Louisville, Kentucky
Conditions
Advanced Clear Cell Renal Cell Carcinoma, Advanced Papillary Renal Cell Carcinoma, Advanced Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Papillary Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Unresectable Clear Cell Renal Cell Carcinoma, Unresectable Renal Cell Carcinoma
Interventions
Cabozantinib S-malate, Clostridium butyricum CBM 588 Probiotic Strain, Nivolumab
Drug · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Duarte, California
Conditions
Fetal Hypoxia
Interventions
GEN 3 Monitoring of Fetus
Device
Lead sponsor
Raydiant Oximetry, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Walnut Creek, California
Conditions
HIV Infections, Kidney Disease, Liver Disease
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
1 Year and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
21
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 12 more
Not listed No phase listed Observational Accepts healthy volunteers

SASH Study - Sonographic Assessment for Severe Hypertension in Pregnancy

NCT03783169
Conditions
Hypertension in Pregnancy
Interventions
Cardiovascular Sonographic Assessment
Other
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Second-Line Uterotonics in Postpartum Hemorrhage: A Randomized Clinical Trial

NCT03584854
Conditions
Postpartum Hemorrhage, Uterine Atony
Interventions
15-methyl prostaglandin F2α, Methylergonovine Maleate
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Carcinoma, Renal Cell
Interventions
Pazopanib, Low Fat Diet
Drug · Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Acute Kidney Injury
Interventions
Vancomycin, Piperacillin-tazobactam, Cefepime
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Secondary Hyperparathyroidism, End-stage Kidney Disease (ESKD)
Interventions
PLS240, Placebo, Open-Label Extension PLS240
Drug
Lead sponsor
Pathalys Pharma
Industry
Eligibility
18 Years to 80 Years
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
49
States / cities
Pine Bluff, Arkansas • Anaheim, California • Beverly Hills, California + 41 more
Conditions
Anemia, Iron Deficiency, Heavy Menstrual Bleeding
Interventions
Ferumoxytol, Ferrous Sulfate
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Ovarian Cancer, Teratoma, Testicular Germ Cell Tumor
Interventions
pegfilgrastim, cisplatin, ifosfamide, paclitaxel
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Recruiting No phase listed Observational Accepts healthy volunteers

Clinical and Genetic Analysis of ROP

NCT04420156
Conditions
Retinopathy of Prematurity
Interventions
No intervention administered.
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
Up to 1 Year
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2030
U.S. locations
5
States / cities
Palo Alto, California • Chicago, Illinois • Royal Oak, Michigan + 2 more
Conditions
Urinary Retention, Prostatic Hyperplasia, Benign Prostatic Hypertrophy
Interventions
Alfuzosin (SL770499)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
55 Years and older · Male only
Enrollment
1,522 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
35
States / cities
Huntsville, Alabama • La Mesa, California • San Bernardino, California + 32 more
Conditions
Congenital Adrenal Hyperplasia
Interventions
Hydrocortisone
Drug
Lead sponsor
Neurocrine UK Limited
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Bladder Neoplasms
Interventions
Not listed
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Houston, Texas
Conditions
Infections, Heart Failure, Chronic Obstructive Pulmonary Disease, Asthma, Gout Flare, Chronic Kidney Diseases, Hypertensive Urgency, Atrial Fibrillation Rapid, Anticoagulation, Diabetes and Its Complications, End of Life/Desires Only Medical Management
Interventions
Home Hospital care, Traditional Hospital care
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Quincy, Illinois • Hazard, Kentucky
Conditions
Cardiovascular Diseases, Diabetes, Gestational Diabetes, Preeclampsia, Gestational Hypertension, Small for Gestational Age at Delivery, Preterm Birth, Overweight and Obesity
Interventions
Fit After Baby, Text4Baby Control Group
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Nephrotic Syndrome, Hyperlipidemia
Interventions
Atorvastatin, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
6 Years to 17 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 1999
U.S. locations
1
States / cities
Dallas, Texas
Recruiting Phase 2 Interventional Accepts healthy volunteers

Prevention of Postpartum Hemorrhage With Tranexamic Acid

NCT05370820
Conditions
Post Partum Hemorrhage
Interventions
Tranexamic acid, No intervention
Drug · Other
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Falls Church, Virginia